-
other groups to share learnings and enhance consistency in best practices across sites, disease areas, and interventional modalities Keep up to date with emerging literature in the area of mechanistic
-
literature in the area of mechanistic modeling and simulation sciences Continue to build a personal track record of publication in the area of PKPD modeling and simulation and contribute to PDM's external
-
MIDD approaches can advance the understanding of pharmacological activity, efficacy and safety Provide support in the development and application of state-of-the-art quantitative methodologies
-
-on expertise in state of the art genetic and epigenetic approaches coupled with next-generation sequencing technologies to gain a broader understanding of MOA and target validation of novel cancer therapeutics